Company Overview and News

0
Industry sees rate hike hurting growth recovery

2018-06-07 freepressjournal.in
New Delhi : The RBI’s decision to increase the key lending rate by 25 basis points will hurt India’s growth prospects and hit business sentiment, the industry said today, and exhorted the central bank to revert to the policy of benign interest rates.
MUTHOOTFIN 533398

6
RBI interest rate hike to hurt India’s growth prospects: Industry

2018-06-06 freepressjournal.in
New Delhi: The industry today said 25 basis points rate hike by the RBI will hurt India’s growth prospects and exhorted the central bank to revert to the policy of benign interest rates.
MUTHOOTFIN HDB 500180 HDFCBANK 533398

0
Muthoot Finance Limited - Updates

2018-05-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MUTHOOTFIN 533398

0
Muthoot Finance stocks slump nearly 8%

2018-05-17 thehindubusinessline
Shares of Muthoot Finance slumped due to lower revenue from financing segment. The stock slumped as much as 7.6 per cent to Rs 387.60, lowest since March 26. The stock posted its biggest daily percentage loss since February 2.
MUTHOOTFIN 533398

31
Market Live: Sensex falls 100 pts as Brent crude inches up towards $80/bbl

2018-05-17 moneycontrol
Market Update: The market is reeling under pressure with the Sensex falling 100 points as investors after digesting Karnataka election outcome started monitoring earnings, and movement in rupee and crude oil prices.
MUTHOOTFIN DVSLY BHRYY 500325 590003 500228 RELIANCE BRIGADE 530239 533398 SUVEN 532343 500470 GRANULES 532482 CENTURYPLY 534816 CAREERP RIGD HDFCBANK INFRATEL 500570 TATAMOTORS RLNIY 532929 TVSMOTOR 533260 IBN 532548 JSWSTEEL 500380 ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 JKLAKSHMI KARURVYSYA TTM

31
Market Live: Sensex, Nifty mildly lower; RIL, HDFC, Infosys, metals stocks drag

2018-05-17 moneycontrol
Crude Update: Oil prices firmed, with Brent crude creeping ever closer to USD 80 per barrel, a level it has not seen since November 2014, as supplies tighten while demand remains strong.
MUTHOOTFIN DVSLY BHRYY 500325 590003 500228 RELIANCE BRIGADE 533398 532343 500470 GRANULES 532482 CENTURYPLY 534816 CAREERP RIGD HDFCBANK INFRATEL 500570 TATAMOTORS RLNIY 532929 TVSMOTOR 533260 IBN 532548 JSWSTEEL 500380 ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 JKLAKSHMI KARURVYSYA TTM

28
Market Live: Sensex, Nifty off opening highs; all sectoral indices in the green barring metals

2018-05-17 moneycontrol
Buzzing: Tata Steel saw profit booking after opening higher as it reported a consolidated net profit of Rs 14,688 crore for the March quarter, as against a loss of Rs 1,168 crore in the same quarter last year, benefiting from a one-time gain of Rs 11,376.14 crore from the restructuring of its UK business' pension scheme.
MUTHOOTFIN DVSLY 590003 500228 BRIGADE 533398 532343 500470 GRANULES 532482 CENTURYPLY CAREERP HDFCBANK 500570 TATAMOTORS 532929 TVSMOTOR 533260 IBN 532548 JSWSTEEL 500380 ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 JKLAKSHMI KARURVYSYA TTM

0
Muthoot Finance to raise up to Rs 6,000 cr via NCDs

2018-05-16 moneycontrol
Muthoot Finance today said it will raise Rs 6,000 crore through public issue of non-convertible debentures (NCDs). "Board of directors of Muthoot Finance in its meeting held on May 16, 2018, has decided to raise funds up to an amount of Rs 6,000 crore by way of public issue(s) of redeemable non-convertible debentures (NCDs)," the company said in a regulatory filing.
MUTHOOTFIN 533398

0
Muthoot Finance Q4 profit jumps 40% at Rs451 crore

2018-05-16 livemint
New Delhi: Muthoot Finance on Wednesday reported 40.3% jump in standalone net profit at Rs451.39 crore for March quarter on the back of diversification of loan portfolio.
MUTHOOTFIN 533398

0
Muthoot Finance Limited - Outcome of Board Meeting

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MUTHOOTFIN 533398

0
Muthoot Finance Limited - Investor Presentation

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MUTHOOTFIN 533398

0
Muthoot Finance Limited - Raising of Funds

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MUTHOOTFIN 533398

0
Muthoot Finance Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MUTHOOTFIN 533398

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...